Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.
Question: Should Monoclonal antibodies compared to Placebo be used for COVID19 patients?
Setting: Outpatient

№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Monoclonal antibodies	Placebo	Relative (95% CI)	Absolute (95% CI)	Certainty
			Certainty assessment				№ of patients		Effect		
All-cause mortality											
2 [1,2]	randomised trials	not serious	not serious	not serious	not serious	none	No deaths reported				⊕⊕⊕⊕ HIGH
Number of patients with any adverse event											
2 [1,2]	randomised trials	not serious	not serious	not serious	not serious	none	96/597 (16.1%)	44/249 (17.7%)	**RR 0.82** (0.60 to 1.12)	**32 fewer per 1.000** (from 71 fewer to 21 more)	⊕⊕⊕⊕ HIGH
Number of patients with serious adverse events											
2 [1,2]	randomised trials	not serious	not serious	not serious	not serious	none	2/597 (0.3%)	3/249 (1.2%)	**RR 0.31** (0.05 to 1.86)	**8 fewer per 1.000** (from 11 fewer to 10 more)	⊕⊕⊕⊕ HIGH
SARS-CoV-2 clearance											
1 [2]	randomised trials	not serious	not serious	not serious	not serious	none	161/418 (38.5%)	56/152 (36.8%)	**RR 1.05** (0.82 to 1.33)	**18 more per 1.000** (from 66 fewer to 122 more)	⊕⊕⊕⊕ HIGH

References

1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
2. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Jan 21:e210202. doi: 10.1001/jama.2021.0202. Epub ahead of print.